Free Trial Information
BioCentury | Jan 6, 2014
Company News

ImmuDyne, Adiuvo Investment deal

...On Dec. 18, 2013, ImmuDyne and biotech investment fund Adiuvo signed a memorandum of understanding to...
...fund Adiuvo signed a memorandum of understanding to form a JV to develop and commercialize ImmuDyne's...
...to treat alcohol abuse. ImmuDyne develops nutritional supplements containing beta glucan to enhance immune responses. ImmuDyne...
Read More
BioCentury | Feb 23, 1998
Clinical News

DynaGen regulatory update

DYGN received notice of allowance for a U.S. patent covering the use of ImmuDyn, a lipid-based immunomodulator, to treat HIV. DYGN's Apex Pharmaceuticals Inc. subsidiary is developing ImmuDyn initially as a therapy for immune thrombocytopenic...
Read More
BioCentury | Jul 28, 1997
Clinical News

ImmuDyn immune modulatory lipid preparation data

DYGN announced preliminary results from a Phase I/II trial that began last fall in India. Patients with ITP received weekly intramuscular injections of 0.5 mg ImmuDyn for 9 weeks. Of the 13 patients enrolled, 11...
Read More
BioCentury | Jul 28, 1997
Clinical News

ImmuDyn immune modulatory lipid preparation data

In a Phase I/II trial in India, 8 HIV-infected patients were given intramuscular injections of 0.5 mg ImmuDyn weekly for 18 weeks and observed for an additional 14 weeks. A decrease in viral load was...
Read More
BioCentury | Apr 18, 1994
Company News

ImmuDyne Inc. deal

...future employment contracts. IMMD is developing immune system stimulants for pharmaceutical, veterinary and agricultural use. ImmuDyne...
Read More
Items per page:
1 - 5 of 5
BioCentury | Jan 6, 2014
Company News

ImmuDyne, Adiuvo Investment deal

...On Dec. 18, 2013, ImmuDyne and biotech investment fund Adiuvo signed a memorandum of understanding to...
...fund Adiuvo signed a memorandum of understanding to form a JV to develop and commercialize ImmuDyne's...
...to treat alcohol abuse. ImmuDyne develops nutritional supplements containing beta glucan to enhance immune responses. ImmuDyne...
Read More
BioCentury | Feb 23, 1998
Clinical News

DynaGen regulatory update

DYGN received notice of allowance for a U.S. patent covering the use of ImmuDyn, a lipid-based immunomodulator, to treat HIV. DYGN's Apex Pharmaceuticals Inc. subsidiary is developing ImmuDyn initially as a therapy for immune thrombocytopenic...
Read More
BioCentury | Jul 28, 1997
Clinical News

ImmuDyn immune modulatory lipid preparation data

DYGN announced preliminary results from a Phase I/II trial that began last fall in India. Patients with ITP received weekly intramuscular injections of 0.5 mg ImmuDyn for 9 weeks. Of the 13 patients enrolled, 11...
Read More
BioCentury | Jul 28, 1997
Clinical News

ImmuDyn immune modulatory lipid preparation data

In a Phase I/II trial in India, 8 HIV-infected patients were given intramuscular injections of 0.5 mg ImmuDyn weekly for 18 weeks and observed for an additional 14 weeks. A decrease in viral load was...
Read More
BioCentury | Apr 18, 1994
Company News

ImmuDyne Inc. deal

...future employment contracts. IMMD is developing immune system stimulants for pharmaceutical, veterinary and agricultural use. ImmuDyne...
Read More
Items per page:
1 - 5 of 5